BENF — Q2 2026 Financial Report Analysis

Paper gains shrank the loss, but the cash and legal problems are unchanged

Beneficient (BENF) lends against stakes in private-equity and other "alternative" funds. Investors who want to exit those hard-to-sell stakes early hand them to trusts Beneficient sets up, and those trusts pay the investor using money (or, more and more often, Beneficient's own stock) supplied by loans from Beneficient. In the quarter to June 30, 2026 (the company's fiscal Q1 2027, since its year ends March 31), the net loss attributable to common shareholders narrowed to $6.8 million from $65.1 million a year earlier. Almost all of that change comes from two things that don't involve cash. The year-ago quarter carried a one-off $62.8 million charge for a lost arbitration case. This quarter, the funds the trusts hold were revalued $15.9 million higher, against a $12.8 million markdown a year earlier. Meanwhile the business used $4.1 million of cash in its operations, ended the quarter with $5.6 million in the bank ($3.4 million by July 31), and its own auditors' framework still requires it to state "substantial doubt" about its ability to keep operating for the next year.

At a glance

• Revenue of $12.2 million vs. minus $12.6 million a year ago: "revenue" here is mostly the change in value of the fund stakes the trusts hold. It swung positive because fund managers reported higher values, not because customers paid Beneficient more.
• $5.6 million cash against roughly $197 million of overdue or contested claims: about $127 million owed to related-party lender HCLP (in default; the company is disputing it after its former CEO's fraud conviction) and a $69.7 million arbitration award it is appealing to the Texas Supreme Court.
• Allowance of $411 million against $597 million of loans: Beneficient itself expects to collect only about 31% of what its trusts owe it. A $3.4 million release of that allowance this quarter is what turned its lending unit's result positive.

Results table

Year-ago per-share figures are adjusted for the 1-for-8 reverse stock split of December 15, 2025. "n/m" = not meaningful because the base is negative. Operating expenses excluding the arbitration charge for Q2 2025: $80.0M minus the $62.8M accrual.

How to read a Beneficient income statement

The company's accounts are unusual, and the headline numbers don't mean what they would at a normal lender.

• The trusts are consolidated, but they aren't Beneficient's. Accounting rules make Beneficient include the customer trusts (it calls them "Customer ExAlt Trusts") in its own statements, even though the trusts' ultimate beneficiaries are charities and their gains and losses mostly flow to "noncontrolling interests" (owners other than Beneficient's shareholders). So the loans Beneficient makes to the trusts, and the interest and fees it charges them, are cancelled out in the consolidated totals.
• What actually reaches shareholders shows up in the segment results. The lending unit, Ben Liquidity, booked $8.2 million of interest income (down from $8.8 million, "primarily driven by a higher percentage of loans being placed on nonaccrual status", meaning loans where it has stopped counting interest because it doesn't expect to be paid). The fee unit, Ben Custody, earned $2.5 million (down from $4.2 million).
• The trusts' side is deeply loss-making: they recorded $40.1 million of interest owed to Ben Liquidity against $15.9 million of investment gains, an operating loss of $27.0 million. Much of that interest is never paid in cash. It is added to the loan balance, and it is why the loan book has grown to $597 million while the collateral behind it is valued at $207.9 million.

What drove the quarter

Revaluations, not new business. Investment income of $15.9 million came from $8.1 million of upward adjustments to fund values reported by the fund managers and $8.0 million of higher quoted market prices, less $0.2 million of currency effects. A year earlier, fund managers had marked values down by $14.6 million. The trusts' fund holdings rose to $179.5 million from $162.8 million at March 31, partly because a new deal closed on April 8: an $8.75 million fund stake, paid for with newly issued Series B-10 convertible preferred stock.

The lending unit's profit came from a credit-loss release. Ben Liquidity's operating income of $7.4 million includes a $3.4 million recovery of credit losses, against a $10.3 million provision a year ago. The filing attributes this to "growth in value of the collateral arising from upward NAV adjustments" and to new transactions. A provision is money set aside for loans not expected to be repaid, so a release adds to profit without any cash coming in. Without it, the unit's operating income would have been about $4.0 million.

Fee income is shrinking because the company is selling assets to raise cash. Custody fees are set as a share of the trusts' asset values. The company says the drop to $2.5 million from $4.2 million reflects lower values, "the primary driver" being its Asset Sales Initiative. It has sold $51.4 million of fund stakes since June 2025, plus another $6.2 million this quarter, to pay creditors and running costs.

Overhead fell, but legal costs haven't gone away. Professional fees fell to $3.5 million from $8.0 million, as costs tied to the GWG bankruptcy settlement (court-approved in January 2026) ended and insurers reimbursed earlier bills. Staff costs dropped to $2.8 million from $3.3 million on lower headcount. Interest expense rose to $4.6 million from $3.4 million, because the $62.8 million arbitration award now accrues post-judgment interest at 10.5%: $1.8 million this quarter.

What the headline numbers hide

• The cash doesn't match the reported result. Consolidated net loss was only $0.4 million, but operations used $4.1 million of cash. The difference is mostly the $15.9 million of fund revaluation gains, which are paper gains. Cash came in from investing activities instead ($6.9 million, mainly $5.0 million of asset-sale proceeds and $1.9 million returned by funds). A company that funds its running costs by selling its collateral can't keep doing so for long.
• The year-ago comparison is distorted by a one-off. Q2 2025 carried the $62.8 million arbitration accrual. Without it, operating expenses fell 27% ($17.2 million to $12.5 million), a real improvement but a far smaller one than the headline drop.
• Management's adjusted figure excludes a lot. Non-GAAP "adjusted operating income" of $5.7 million (a measure the company defines itself, outside standard accounting rules) adds back a $3.8 million loss on a derivative, the $1.8 million of arbitration interest, $0.4 million of lawsuit-related legal fees and $0.2 million of stock compensation. The arbitration interest is a real, growing obligation, so excluding it flatters the picture.
• The derivative loss is real but unusual. In October 2025, insiders (former chairman Thomas Hicks and CEO James Silk) converted $52.6 million of a subsidiary's preferred units into 12.66 million Class A shares. They agreed to give back shares equal to any rise in the stock's value through a lock-up ending in 2028. That give-back right is valued as an asset ($17.9 million at June 30). It fell $3.8 million this quarter, which reflects the stock price and doesn't cost cash.
• The per-share loss is almost meaningless. The -$0.47 figure divides about $0.85 million of loss by only 1.83 million weighted Class A shares. The 12.66 million conversion shares are left out of the count because they might be partly forfeited, and $5.9 million of the loss is assigned to other "participating securities." At June 30 there were 14.77 million Class A shares outstanding. The -$57.55 a year ago reflected a much smaller share count after the 1-for-8 reverse split, so the two numbers can't be compared.
• The line between consolidated results and shareholders' results. From the -$0.4 million consolidated loss, the trusts' outside beneficiaries took $1.5 million of income. A $4.9 million "guaranteed payment" also accrued to holders of BCH Preferred A-0, a senior class of preferred units in a subsidiary. That payment has not been made in cash: unpaid accruals reached $79.3 million. Those two items take the result down to the -$6.8 million attributable to common shareholders.
• Dilution is the funding model. New deals are paid for in convertible preferred stock. The Series B-10 shares issued in April could convert into up to 7.05 million Class A shares at a floor price of $1.24, and the B-11 shares issued in July into up to 4.08 million. On top of that, a $100 million equity line with Yorkville has 32.5 million shares registered, and Yorkville has advanced $4.0 million in convertible notes since July 1. Each of these could add a large share of the 14.77 million shares now outstanding.

The solvency picture

Total liabilities of $344.5 million exceed total assets of $250.9 million, leaving shareholders' equity at minus $184.1 million, with another $90.5 million of redeemable preferred units ranking ahead of common shareholders. The two claims that matter most:

• HCLP loan, about $127 million including interest: the lender declared default in July 2025. Beneficient says it is evaluating whether it owes the money at all. At former CEO Brad Heppner's trial, it was established that he fabricated the HCLP loan and controlled HCLP. He was convicted of securities fraud, wire fraud and false statements to auditors on May 7, 2026.
• Arbitration award, $69.7 million with interest: owed to a former director over cancelled equity awards. An appeals court confirmed it in October 2025. Beneficient has petitioned the Texas Supreme Court. Instead of the $25 million appeal bond the trial court ordered, it posted a $100 cash bond, after filing a sworn declaration that its net worth is negative.

Takeaway: The narrower loss is about valuations and a missing one-off charge, not a business turning around. The company that reaches shareholders brought in about $10.7 million of interest and fees and spent cash faster than it earned it. It funds itself by selling its collateral and issuing convertible stock, while about $197 million of disputed or overdue claims sit against $5.6 million of cash. Its future depends on court outcomes more than on operating results.

What to watch next

Management gave no financial guidance. The next 10-Q, for the quarter ending September 30, 2026, would normally be due in mid-November. Things that would change the picture:

• The Texas Supreme Court petition on the $69.7 million award, and any settlement. The company says it is "exploring" one.
• The HCLP dispute. If Beneficient can show the $127 million obligation is invalid after Heppner's conviction, its balance sheet changes dramatically. If it can't, the claim far exceeds what the company can pay.
• Cash runway. Cash fell from $5.6 million to $3.4 million in July even after a $1.9 million Yorkville advance on July 1. Watch how much more stock goes to Yorkville and to holders converting B-series preferred.
• Whether the credit-loss releases last. This quarter's profit in the lending unit depended on fund managers marking values up. With 88% of the trusts' 375 underlying investments in private companies, those values can be marked down just as easily.
• New business lines. The company signed its first collateral-management engagement, monitoring alternative assets pledged to a Texas bank. It is expected to bring recurring fees, but the filing gives no amount.

Our read: until the two big legal claims are resolved, Beneficient's quarterly results matter less than the court rulings. Its operating income per quarter is small next to those claims, and equity issuance is likely to keep growing the share count.

Source: Beneficient Form 10-Q for the quarter ended June 30, 2026, filed August 14, 2026. All figures are from that filing; dollar amounts are rounded.